|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.14 USD | -4.09% |
|
-13.71% | +55.87% |
| 11:35am | Moderna, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 10:00 AM | |
| May. 18 | US states reject anti-vaccine bills as public health groups fight MAHA | RE |
Business description: Moderna, Inc.
- revenue from product sales (96.1%);
- revenue from collaboration agreements (1.5%);
- revenue from royalties and licensing (1.3%);
- revenue from grants (1.1%).
At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase.
Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Number of employees: 4,700
Sales by Activity: Moderna, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology | 18.47B | 19.26B | 6.85B | 3.24B | 1.94B |
Geographical breakdown of sales: Moderna, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 6.18B | 5.15B | 1.9B | 1.78B | 1.2B |
Rest of World | 5.45B | 7.3B | 3.6B | 853M | 692M |
Europe | 6.85B | 6.82B | 1.36B | 598M | 53M |
Executive Committee: Moderna, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 49 | 2022-09-05 |
Stephen Hoge
PSD | President | 50 | 2024-10-31 |
Jerh Collins
CTO | Chief Tech/Sci/R&D Officer | - | 2022-12-31 |
Tracey Franklin
CTO | Chief Tech/Sci/R&D Officer | 46 | 2024-11-06 |
Composition of the Board of Directors: Moderna, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 62 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 69 | 2019-12-10 |
Sandra Horning
BRD | Director/Board Member | 77 | 2020-02-29 |
| Director/Board Member | 77 | 2020-06-30 | |
Elizabeth Nabel
BRD | Director/Board Member | 74 | 2015-11-30 |
David Rubenstein
BRD | Director/Board Member | 76 | 2024-08-04 |
Shah Hussain
BRD | Director/Board Member | 61 | 2024-10-01 |
Holdings: Moderna, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
CARISMA THERAPEUTICS, INC. 12.09% | 5,059,338 | 12.09% | 2 530 $ |
Company details: Moderna, Inc.
Group companies: Moderna, Inc.
| Name | Category and Sector |
|---|---|
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Develops messenger RNA therapeutics |
Biotechnology
|
Moderna Switzerland GmbH |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.82% | -13.73% | +74.14% | -63.60% | 19.09B | |
| +0.60% | -12.41% | +6.22% | -16.52% | 64.06B | |
| +2.17% | -0.38% | +48.16% | +170.50% | 50.94B | |
| -2.89% | +34.60% | +34.60% | +34.60% | 42.87B | |
| +2.77% | -2.04% | -59.19% | -67.41% | 33.4B | |
| -0.56% | -4.20% | +47.54% | -38.09% | 28.33B | |
| +0.26% | -3.59% | +49.77% | +50.34% | 19.02B | |
| -0.37% | -9.35% | +56.86% | +111.08% | 17.79B | |
| +0.05% | -1.09% | +40.58% | +82.06% | 15.96B | |
| +2.52% | +12.77% | +15.43% | +731.07% | 12.78B | |
| Average | -0.10% | -4.82% | +31.41% | +99.40% | 30.42B | |
| Weighted average by Cap. | +0.01% | -5.69% | +26.04% | +59.66% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
- Company Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
